368 results on '"Dejager, S."'
Search Results
2. Le diabète de type 2 au stade de l’insuline : Quelle place pour les inhibiteurs de la DPP-4 ?
3. Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study
4. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database
5. Physical activity in patients with type 2 diabetes and hypertension – insights into motivations and barriers from the MOBILE study
6. Vildagliptine versus sitagliptine en addition à la metformine : sont-elles équivalentes ? Résultats de l’étude OPTIMA
7. Étude HYPOCRAS : comparaison en vie réelle chez des patients âgés diabétiques de type 2 d’un traitement par inhibiteur de la DPP-4 versus autres antidiabétiques oraux en ajout à la metformine
8. Near normal HbA1c with stable glucose homeostasis: the ultimate target/aim of diabetes therapy
9. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study
10. Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
11. Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: The HYPOCRAS study
12. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study
13. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
14. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
15. How patients’ attitudes and opinions influence self-care behaviours in type 2 diabetes. Insights from the French DIABASIS Survey
16. Efficacy of a Medical Directive to Reduce Inappropriate Indwelling Urinary Catheter Use on Orthopedic Wards
17. Enquête Diabasis : perception et vécu du diabète par les patients diabétiques: Diabasis survey: Patients’ life experience and perception of the disease
18. Enquête Diabasis : comment le patient diabétique perçoit son traitement et son suivi ?: Diabasis survey: How the diabetic patient perceives his treatment and follow-up?
19. How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS survey
20. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
21. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans
22. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials
23. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
24. Assessing the cardio–cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
25. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
26. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
27. Robust improvements in fasting and prandial measures of β-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database
28. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naïve patients with Type 2 diabetes
29. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
30. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
31. Prevalence of low HDL-cholesterol in patients with cardiovascular risk factors: the ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey
32. Octreotide (Long-Acting Release Formulation) Treatment in Patients with Graves’ Orbitopathy: Clinical Results of a Four-Month, Randomized, Placebo-Controlled, Double-Blind Study
33. Étude pacifique : postangioplastie coronaire en France et intervention thérapeutique
34. A Comprehensive Endocrine Description of Kennedy’s Disease Revealing Androgen Insensitivity Linked to CAG Repeat Length
35. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls
36. Sheehan's syndrome: differential diagnosis in the acute phase
37. Le coût des hospitalisations pour hypoglycémie en France chez les patients diabétiques de type 2
38. Des essais randomisés contrôlés aux études observationnelles. Apports, limites et leçons. Réflexions à propos de l’étude ODYSSEE
39. Étude observationnelle ODYSSEE : durée de maintenance de la bithérapie metformine-sitagliptine versus metformine-sulfamides hypoglycémiants chez des patients diabétiques de type 2
40. Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?
41. CA-155: Supprimer les barrières à une gestion du diabète de type 2 efficace : résultats de l'utilisation de l'outil OPTIMA en pratique courante
42. CO-26: Quel traitement antidiabétique oral combiner à la metformine à l'initiation de l'insuline basale chez des diabétiques de type 2 ? Un essai contrôlé randomisé vildagliptine versus insulino-sécrétagogues
43. CO-20: Physical activity in patients with type 2 diabetes and hypertension – insights into motivations and barriers from the MOBILE study
44. Variabilité glycémique et hyperglycémie postprandiale : quelle importance au-delà del’HbA1c?
45. P097 Fréquence des hospitalisations pour hypoglycémies sous vildagliptine et sous insulino-sécrétagogue: une analyse des données de l’EGB de l’assurance maladie
46. P004 L’activité physique des médecins a une influence sur le contrôle glycémique et tensionnel de leurs patients diabétiques et hypertendus : enseignements de l’étude MOBILE
47. P002 Barrières et motivations à la pratique de l’activité physique chez des patients diabétiques et hypertendus : premiers enseignements de l’étude MOBILE
48. O25 Les patients âgés diabétiques de type 2 avec maladie rénale chronique sont-ils sur-traités en France ? Enseignements de l’étude OREDIA
49. Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride
50. GLP-1: What is known, new and controversial in 2010?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.